Merck's Q4 2011 earnings reported a positive year with sales and EPS growth, indicating strong operational performance. The company navigated well-known challenges like SINGULAIR's patent expiration, while making strategic investments in high-growth markets and new product launches. However, anticipated pricing pressure in Europe, a cautious approach to future revenue forecasts, and the annualization effects of previous sales transitions might result in mixed market reactions.
[0]